Lysergic acid diethylamide LSD
Current Therapeutics August 1, 2001 Peer reviewed via Elsevier
Abstract
No abstract available from the source.
Related reading
- Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience. Pharmaceuticals (Basel, Switzerland) • March 29, 2025 • via PubMed
- Identification of two lysergic acid diethylamide analogs, 1-(3-(trimethylsilyl) propionyl) lysergic acid diethylamide (1S-LSD) and 1-(2-thienoyl)-6-allyl-nor-d-lysergic acid diethylamide (1T-AL-LAD), in paper sheet products distributed on the internet. Forensic toxicology • April 3, 2025 • via PubMed
- Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably? Psychedelic medicine (New Rochelle, N.Y.) • June 1, 2024 • via PubMed
- Modification of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method targeting lysergic acid diethylamide (LSD) and its primary metabolite (OH-LSD) to include nine LSD analogs. Journal of forensic sciences • September 1, 2024 • via PubMed
- A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)‐ and psilocybin‐related death in Australia Addiction • May 21, 2024 • via OpenAlex